RBM39 as a Therapeutic Target in Acute Lymphoblastic Leukemia: Disruption of Cotranscriptional Splicing

Research Summary Potential of Targeting RBM39 in High-Risk Acute Lymphoblastic Leukemia (B-ALL) Background Overview Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy commonly diagnosed in children and young adults. Despite high remission rates through frontline chemotherapies, the long-term survival rate for patients with relapsed/re...

Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations

Report on the Academic Paper: Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations Academic Background and Research Motivation Telomere biology disorders (TBDs) are a group of diseases caused by pathogenic germline variants (PGVs) in telomere-related genes, manifesting with multi-organ dysfunctio...

Ide-cel vs Standard Regimens in Triple-Class–Exposed Relapsed and Refractory Multiple Myeloma: Updated KARMMA-3 Analyses

Latest Research Report: Idecabtagene Vicleucel (ide-cel) Significantly Extends Progression-Free Survival in Triple-Class Exposed (TCE) Relapsed or Refractory Multiple Myeloma – Results from the KARMMA-3 Clinical Trial Academic Background and Research Question Patients with Multiple Myeloma (MM) often relapse after multiple lines of therapy, with pr...

Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T-Cell Acute Lymphoblastic Leukemia

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...

Bleeding Events in Patients with Cancer: Incidence, Risk Factors, and Impact on Prognosis in a Prospective Cohort Study

The Incidence, Risk Factors, and Prognostic Impact of Bleeding Risk in Cancer Patients: A Review of the Vienna Cancer, Thrombosis, and Bleeding Study Academic Background and Research Motivation Cancer patients frequently experience hemostatic dysregulation, yet existing research has primarily focused on cancer-associated venous thromboembolism (VTE...